Probiotics modulate intestinal expression of nuclear receptor and provide Counter-Regulatory signals to Inflammation-Driven adipose tissue activation

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Mencarelli, Andrea ^a   Distrutti, Eleonora ^b   Renga, Barbara ^a   D'Amore, Claudio ^a   Cipriani, Sabrina ^a   Palladino, Giuseppe ^a   Donini, Annibale ^c   Ricci, Patrizia ^c   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c Nuova Facoltà di Medicina e Chirurgia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CELL NUCLEUS RECEPTOR; CIPROFLOXACIN; FARNESOID X RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 6; LEPTIN; LIVER X RECEPTOR; METRONIDAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREGNANE X RECEPTOR; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VSL3; CELL RECEPTOR; CYTOKINE; FARNESOID X-ACTIVATED RECEPTOR; MESSENGER RNA; ORPHAN NUCLEAR RECEPTOR; STEROID RECEPTOR; TRINITROBENZENESULFONIC ACID;

ABDOMINAL ABSCESS; ABDOMINAL FAT; ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; ENTERITIS; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; INFLAMMATION; INTESTINE CELL; INTESTINE FISTULA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE CULTURE; TISSUE LEVEL; TREATMENT DURATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; GENETICS; INTESTINE; MESENTERY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALIA; MUS; RODENTIA;

ADIPOSE TISSUE; ADULT; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; COLITIS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; INTESTINES; MALE; MESENTERY; MICE; ORPHAN NUCLEAR RECEPTORS; PPAR GAMMA; PROBIOTICS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRINITROBENZENESULFONIC ACID;

EID: 79960963699     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022978     Document Type: Article

References (48)

1. Sheehan AL, Warren BF, Gear MW, Shepherd NA, (1992) Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 79: 955-958.
2. Smedh K, Olaison G, Nyström PO, Sjödahl R, (1993) Intraoperative enteroscopy in Crohn's disease. Br J Surg 80: 897-900.
3. Borley NR, Mortensen NJ, Jewell DP, Warren BF, (2000) The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link. J Pathol 190: 196-202.
4. Fazio VW, Jones IT, (1987) Standard surgical treatment of Crohn's disease of the small intestine and ileocolitis. In: Lee ECG, Nolan DJ, eds. Surgery of inflammatory bowel disorders. Edinburgh: Churchill Livingstone 147-56.
5. Paul G, Schäffler A, Neumeier M, Fürst A, Bataillle F, et al. (2006) Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 12: 471-477.
6. Schaffler A, Herfarth H, (2005) Creeping fat in Crohn's disease: travelling in a creeper lane of research? Gut 54: 742-744.
7. Boss O, Bergenhem N, (2006) Adipose targets for obesity drug development. Expert Opin Ther Targets 10: 119-134.
8. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101: 15718-15723.
9. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI, (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 104: 979-984.
10. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, et al. (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455: 1109-1113.
11. Einarsson K, Gustafsson JA, Gustafsson BE, (1973) Differences between germfree and conventional rats in liver microsomal metabolism of steroids. J Biol Chem 248: 3623-3630.
12. Gustafsson BE, Angelin B, Einarsson K, Gustafsson JA, (1977) Effects of cholesterol feeding on synthesis and metabolism of cholesterol and bile acids in germfree rats. J Lipid Res 18: 717-721.
13. Einarsson K, Gustafsson JA, Gustafsson BE, (1977) Hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in germfree rats. Proc Soc Exp Biol Med 154: 319-321.
14. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, et al. (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J Exp Med 193: 827-838.
15. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK, (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage function. Nature 391: 79-82.
16. Jiang C, Ting AT, Seed B, (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86.
17. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, et al. (2001) PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Med 7: 48-52.
18. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S, (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183: 6251-6261.
19. Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, et al. (2009) Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 15: 1721-1736.
20. Lam B, Younossi ZM, (2010) Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 3: 121-137.
21. Fiorucci S, Mencarelli A, Palazzetti B, Sprague AG, Distrutti E, et al. (2002) Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity 17: 769-780.
22. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P, (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med 9: 213-219.
23. Fiorucci S, Cipriani S, Mencarelli A, Renga B, Distrutti E, et al. (2010) Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med 10: 579-595.
24. Chapman TM, Plosker GL, Figgit DP, (2006) VSL#3 probiotics mixture. A review of its use in chronic inflammatory bowel disease. Drugs 66: 1371-1387.
25. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, et al. (2001) Probiotics bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591.
26. Kühbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, et al. (2006) Bacterial and fungal microbiota in relation to probiotics therapy (VSL#3) in pouchitis. Gut 55: 833-841.
27. Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C, (2005) The VSL#3 probiotics mixture modifies microflora but does not heal chronic dextran-sodium sulphate induced colitis or reinforce the mucosal barrier in mice. J Nutr 135: 2753-2761.
28. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, et al. (2008) Probiotics administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14: 662-668.
29. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M, (2005) Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol 174: 3237-3246.
30. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, et al. (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127: 26-40.
31. Kershaw EE, Flier JS, (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556.
32. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, et al. (1999) Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 117: 73-81.
33. Schaffler A, Scholmerich J, Buchler C, (2005) Mechanisms of disease: Adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2: 273-280.
34. Karagiannides I, Kokkotou E, Tansky M, Tchkonia T, Giorgadze N, et al. (2006) Induction of colitis causes inflammatory responses in fat depots: Evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci U S A 103: 5207-5212.
35. Fernandez-Real JM, Ricart W, (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24: 278-301.
36. Brun RP, Kim JB, Hu E, Spiegelman BM, (1997) Peroxisome proliferator-activated receptor gamma and the control of adipogenesis. Curr Opin Lipidol 8: 212-218.
37. Buechler C, Wanninger J, Neumeier M, (2010) Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways. FEBS Lett 584: 4280-4286.
38. Paul G, Schäffler A, Neumeier M, Fürst A, Bataillle F, et al. (2006) Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 12: 471-477.
39. Rizzo G, Disante M, Mencarelli A, Renga B, Gioiello A, et al. (2006) The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol 70: 1164-11673.
40. Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, et al. (2010) The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 285: 36759-36767.
41. Yoshinari K, Sato T, Okino N, Sugatani J, Miwa M, (2004) Expression and induction of cytochromes p450 in rat white adipose tissue. J Pharmacol Exp Ther 311: 147-154.
42. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P, (1995) Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269: 546-549.
43. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, et al. (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161.
44. Ballinger A, Kelly P, Hallyburton E, Besser R, Farthing M, (1998) Plasma leptin in chronic inflammatory bowel disease and HIV: implications for the pathogenesis of anorexia and weight loss. Clinical Science 94: 479-483.
45. von der Weid PY, Rainey KJ, (2010) Review article: lymphatic system and associated adipose tissue in the development of inflammatory bowel disease. Aliment Pharmacol Ther 32: 697-711.
46. Marra F, Bertolani C, (2009) Adipokines in liver diseases. Hepatology 50: 957-69.
47. Wu GD, (2003) Is there a role for PPAR gamma in IBD? Yes, no, maybe. Gastroenterology 124: 1538-42.
48. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al. (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association, Diabetes Care 27: 256-263.